VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.02 USD
+0.10 (3.42%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
VTGN 3.02 +0.10(3.42%)
Will VTGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTGN
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
Other News for VTGN
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update